Drug class
Kinase Inhibitor
Mechanism of action
Proto-Oncogene Tyrosine-Protein Kinase ROS1 Inhibitors [MoA]
General use cases
- • adult patients with locally advanced or metastatic ROS1- positive non-small cell lung cancer (NSCLC)
- adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) [see Dosage and Administration (2
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
